Ghiorghiu, Serban
AstraZeneca (United Kingdom) · Army Medical University · Chinese University of Hong Kong · Guangdong General Hospital · Samsung Medical Center · Guangdong Academy of Medical Sciences · State Key Laboratory of Oncology in South China · Sungkyunkwan University
4 papers on CoChatORCID 0009-0006-6879-9113
Most cited papers
- Verified
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 3,379
- Verified
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 2,246
- Verified
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 2,116
- Verified
Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 571
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free